Scoring a bull's-eye against cancer genome targets

Current Opinion in Pharmacology

Volumn 1, Issue 4, 2001, Pages 342-352

  Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Deacetylation targets; Genetics; Histone acetylation; Human and cancer genome sequences; Kinase targets; Mechanism based drugs; Molecular Medicine; New molecular targets; Pharmacology

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; HISTONE DEACETYLASE; PHOSPHOTRANSFERASE;

DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; GENOME; HUMAN; METABOLISM; NEOPLASM; REVIEW;

ARYLAMINE N-ACETYLTRANSFERASE; GENOME, HUMAN; HISTONE DEACETYLASES; HUMANS; NEOPLASMS; PHOSPHOTRANSFERASES;

EID: 0035431318     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00060-1     Document Type: Review

References (74)

1. De Vita V.T., Hellman S., Rosenberg S.A. Cancer: Principles and Practice of Oncology. edn 6 :2001;Lippincott, Philadelphia. The latest ediition of the standard oncology reference book (the oncology bible!).
2. Sikora K., Advani S., Koroltchouk V., Magrath I., Levy L., Pinedo H., Schwartsmann G., Tattesall M., Yan S. Essential drugs for cancer therapy: a World Health Organisation consultation. Ann Oncol. 10:1999;385-390. A critical survey of the utility of cancer drugs.
3. Garret M.D., Workman P. Millennium review. Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer. 35:1999;2010-2030. A lengthy review of the development of anticancer agents acting on new molecular targets.
4. Workman P. Towards genomic cancer pharmacology: innovative drugs for the new millennium. Curr Opin Oncol Endocrine Metab Invest Drugs. 2:2000;21-25. A concise editorial on post-genomic cancer drug development, focusing on the improved understanding of the molecular causation of various cancers and the implementation of high-throughput technologies to increase the speed and efficiency and drug development.
5. Gibbs J.B. Mechanism-based target identification and drug discovery in cancer research. Science. 287:2000;1969-1973. A timely review of new mechanism-based cancer drugs acting on novel molecular targets. Focuses on breast cancer as a paradigm.
6. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921. Landmark publication by the international public consortium, of the working draft of the human genome sequence. The availability of the genome sequence is revolutionising biology and medicine.
7. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., Smith H.O., Yandell M., Evans C.A., Holt R.A., et al. The sequence of the human genome. Science. 291:2001;1304-1351. The human genome sequence as published by the private company Celera Genomics.
8. Davies K: The Sequence: Inside the Race for the Human Genome. London: Weidenfield and Nicolson; 2001. (Also published in the USA under the title Cracking the Genome: Inside the Race to Unlock Human DNA by The Free Press.). A description of the science, personalities and politics behind the sequencing of the human genome. Gives several examples of how the sequence benefits cancer research, including the discovery of new cancer genes and drug targets. Excellent reading at 35 000 feet.
9. Brent R. Genomic biology. Cell. 100:2000;169-183. An excellent review that illustrates how the practice of biology is revolutionised by genomics.
10. Jiminez-Sanchez G., Childs B., Valle D. Human disease genes. Nature. 409:2001;853-855. A commentary on the implications of the discovery of human disease genes, which accompanied the publication of the human genome sequence.
11. Baltimore D. Our genome unveiled. Nature. 409:2001;814-815. General commentary on the human genome sequence.
12. Editorial: The human genome, in proportion. Lancet 2001, 35: 74-89. A note of caution, setting the potential value of the genome sequence in the context of factors affecting human health world-wide and also the costs of healthcare.
13. Editorial: A cold dose of medicine. Nat Biotechnol 2001, 19: 181. Another cautionary note, emphasising the need for greater understanding of proteomics and metabolic pathways, together with the challenge of moving from genes to drugs.
14. Futreal P.A., Ksprzyk A., Birney E., Mullikin J.C., Wooster R., Stratton M.R. Cancer and genomics. Nature. 409:2001;850-855. An early look at the potential for discovery of new cancer genes using the published working draft of the human genome sequence and the available cancer genome sequences. This illustrates the need for high-quality genome-wide sequencing of the genomes of cancer cells and tissues.
15. Editorial: All hands on deck at dawn. Nat Genet 2001, 27:347-349. A commentary on the Oncogenomics Conference. (Tucson, Arizona 25-27 January 2001). Held just before the publication of the draft human genome sequence, the meeting provided a preview of the highlights and an opportunity to discuss the implications for cancer research and therapy.
16. Ratain M.J., Relling M.V. Gazing into a crystal ball - cancer therapy in the post-genome era. Nat Med. 7:2001;283-285. A thoughtful commentary that predicts that genome sequencing, the discovery of cancer genes and the elucidation of the molecular pathogenesis of cancer will lead to an age of individually tailored drugs - but it will take time for this to impact on routine cancer therapy.
17. Golub T.R. Genome-wide views of cancer. New Engl J Med. 344:2001;601-602. This editorial discusses issues around the impact of genomics on cancer diagnosis and therapy, with particular reference to DNA microarrays in general and the transcriptional signatures of mutant BRCA1 and BRCA2 in particular.
18. Perou C.M., Serlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., et al. Molecular portraits of human breast tumours. Nature. 406:2000;747-752. One of the first published studies determining global gene expression profiles in human tumours, in this case for breast cancer.
19. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 286:1999;531-537. Another early determination of gene expression profiles in human cancer. This example, in lymphoma, illustrates the ability to discover and predict subclasses within that tumour type.
20. Stratowa C., Wilgenbus K.K. Gene expression profiling in drug discovery. Curr Opin Mol Ther. 1:1999;671-679. A valuable review illustrating the power of gene expression profiling - a technique that will impact on all phases of target and drug discovery.
21. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, et al.: Systematic variation in gene expression patterns in human cancer cell lines, Nat Genet, 24:227-235. Characterisation of gene expression patterns using DNA microarrays in the US National Cancer Institute's panel of 60 human tumour cell lines.
22. Scherf U., Ross D.T., Waltham M., Smith L.H., Lee J.K., Tanabe L., Kohn K.W., Reinhold W.C., Myers T.G., Andrews D.T., et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet. 24:2000;227-235. Describes the use of informatics programmes to mine the gene expression database (from [21•]) and determine correlations with sensitivity to >10 000 compounds in the 60 cell line panel.
23. Knight J. When the chips are down. Nature. 410:2001;860-861. An important news feature that points out inaccuracies in gene identity on microarrays.
24. Kudoh K., Ramanna M., Ravatn R., Elkahloun A.G., Bittner E.L., Meltzer P.S., Trent J.M., Dalton W.S., Chin K.V. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60:2000;4161-4166. One of the first papers to use microarrays to determine global gene expresion changes in response to drug treatment - in this case for the cytotoxic agent doxorubicin.
25. Clarke P.A., Hostein I., Banerji U., Di Stefano F., Maloney A., Walton M., Judson I., Workman P. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxy geldanamycin, an inhibitor of the Hsp90 molecular chaperone. Oncogene. 19:2000;4125-4133. Another of the first papers to use microarrays to determine global gene expression changes in response to drug treatment - here the agent is the Hsp90 molecular chaperone inhibitor 17AAG. This study identified genes that may be useful in predicting sensitivity to the drug, as well as pharmacodynamic response markers.
26. Hahn W.C., Counter C.M., Lundberg A.S., Bijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature. 400:1999;464-468. Creating cancerous human epithelial cells in the laboratory by deregulating the function of four critical genes: Harvey Ras, p53, Rb and the telomerase catalytic subunit hTERT.
27. Vogelstein B., Kinzler K. The multistep nature of cancer. Trends Genet. 9:1993;138-141.
28. Claverie J.M. What if there are only 30 000 human genes? Science. 291:2001;1255-1257. An interesting discussion of the predicted human gene count.
29. Sorek R., Amitai M. Piecing together the significance of splice. Nat Biotechnol. 19:2001;196. A commentary on significance of splice variants.
30. Drews J. Genomic sciences and the medicine of tomorrow. Nat Biotechnol. 14:1996;1518-1519.
31. Drews J. Drug discovery: a historical perspective. Science. 287:2000;1960-1964. An update on the classic commentary [30].
32. Bailey D., Zanders E., Dean P. The end of the beginning for genomic medicine. Nat Biotechnol. 19:2001;207-209. An interesting commentary that suggests that the number of new drug targets may exceed the original estimate of 6-10 000 despite the reduction in the predicted human gene count.
33. Floyd C., Le Blanc C., Whittaker M. Combinatorial chemistry as a tool for drug discovery. Prog Med Chem. 36:1999;91-167. A review of combinatorial chemistry that is relatively accessible for bioscientists.
34. Gullier F., Orain D., Bradley M. Linkers and cleavage strategies in solid-phase organic synthesis and combinatorial chemistry. Chem Rev. 100:2000;2091-2157. A more detailed review of technical developments in combinatorial chemistry.
35. Schreiber S.L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science. 287:2000;1964-1969. Describes approaches for planning, by retrosynthetic analysis, both diversity-oriented synthetic libraries and more focused target-oriented libraries for drug discovery.
36. End D.W., Smets G., Todd A.V., Applegate T.L., Fuery C.J., Angibaud P., Venet M., Sanz G., Poignet H., Skrzat S., et al. Characterisation of the antitumour effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 61:2000;131-137. An example of a farnesyl transferase inhibitor, these results suggest that antitumour activity may be due, in part, to effects on host-tumour interactions.
37. Rowinsky E.K., Windle J.J., Von Hoff D.D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 17:1999;3631-3652. A review of farnesyl transferase inhibitors.
38. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-312. An up-to-date and readable review of p53.
39. Khuri F.R., Nemunaitis J., Ganly I., Arseneau J., Tannock I.F., Romel L., Gore M., Ironside J., MacDougall R.H., Heise C., et al. A controlled trial of intratumoral Onyx-O15, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 6:2000;879-885. This paper describes progress in the clinical development of the Onyx adenovirus which selectively replicates in, and kills, tumour cells that lack p53 function.
40. Komarov P.G., Komarov E.A., Kondratov R.V., Christov-Tselkov K., Coon J.S., Chemov M.V., Gudkov A.V. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 285:1999;1733-1737. Discovery through screening, of a small molecule (pifithrin-α), that inhibits p53-dependent gene expression and protects against the side-effects of DNA-damaging agents.
41. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science. 286:1999;2507-2510. Another approach to cancer therapy based on p53. Here, screening was used to discover small molecules that stabilize mutant p53 in the wild-type, functionally active conformation. These agents show antitumour activity in cancer models in vivo.
42. Walters W.P., Ajay, Murcko M.A. Recognising molecules with drug- like properties. Curr Opin Chem Biol. 3:1999;384-387. Designing 'drug-like' behaviour into a lead series is a major hurdle in drug discovery. This review summarises the development of tools to enrich chemical libraries for these desirable properties.
43. Raynaud F.I., Goddard P., Fischer P., McClue S., Workman P. Cassette dosing pharmacokinetics for 107 analogue of the trisubstituted purine CDK2 inhibitor Roscovitine. Proc Am Assoc Cancer Res. 42:2001;382. This abstract exemplifies the value of using cassette dosing to select anticancer compounds with good pharmacokinetic properties.
44. Hanahan D., Weinberg A. The hallmarks of cancer. Cell. 100:2000;57-70. A superb and highly readable review of the molecular causes of cancer.
45. Levitski A., Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 267:1995;1782-1788.
46. McLeod A.L., Brunton V.G., Eckhardt N., Lear M.J., Robins D.J. In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022. Br J Cancer. 74:1996;1714-1718.
47. Strawn L.M., Shawver L.K. Tyrosine kinases in disease. Exp Opin Invest Drugs. 7:1998;553-573.
48. Druker B.J., Talpaz M., Rest D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med. 344:2001;1031-1037. A much anticipated Phase 1 study report describing the exciting results obtained with the Bcr-Abl kinase inhibitor Glivec® in chronic myeloid leukaemia. Provides proof of principle for the development of anticancer drugs based on a specific molecular abnormality that drives the particular cancer.
49. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New Engl J Med. 344:2001;1038-1042. Confirmation that Glivec® is well tolerated and active in chronic myeloid leukemia, including the blast crisis phase, and also in Philadelphia chromosome positive acute lymphocytic leukaemia.
50. Schinder T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science. 289:2000;1938-1941. A structural explanation for the inhibition of the Abl tyrosine kinase by Glivec®.
51. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D., Silberman S.L., Capdeville R., Dimitrijevic S., Druker B.J., Demetri G.D. Effect of the tyrosine kinase inhibtior ST1571 in a patient with a metastatic gastrointestinal stromal tumor. New Engl J Med. 344:2001;1052-1056. Demonstration of the potential for Glivec® activity in GIST tumours that have activated c-kit tyrosine kinase.
52. Baselga J., Averbuch S.D. ZD1839 ('Iressa') as an anticancer agent. Drugs. 60:2000;33-40. Iressa is showing promising clinical activity as an inhibitor of the EGF receptor tyrosine kinase.
53. Slamon D., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med. 344:2001;783-792. This paper shows a survival advantage for the use of the anti-erbB2 antibody Herceptin® when used as part of combination chemotherapy for the treatment of metastatic breast cancer.
54. Fry D.W., Garrett M.D. Inhibitors of cyclin-dependent kinases as therapeutic agents for the treatment of cancer. Curr Opin Oncol Endocrine Metab Invest Drugs. 2:2000;40-59. An up-to-date review of the discovery of cyclin-dependent kinase targets and inhibitors acting on these.
55. Stein R.C., Waterfield M.D. PI3-kinase inhibition: a target for drug development? Mol Med Today. 6:2000;347-357. A commentary that explores the potential of PI3Ks as drug targets.
56. Kelland L.R., Sharp S.Y., Rogers P.M., Myers T.G., Workman P. DT-diaphorase expression and tumour cell sensitivity to 17-allylamino,17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst. 91:1999;1940-1949. Demonstration of the antitumour activity of the Hsp90 inhibitor 17AAG against human tumour xenografts, and the role of DT-diaphorase in tumour sensitivity to this inhibition.
57. Hostein I., Robertson D., Di Stefano F., Workman P., Clarke P.A. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. 61:2001;4003-4009.
58. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev. 9:1999;40-48. A review of the key role played by mammalian HATs and HDACs in the control of gene transcription and cell proliferation, also highlighting their potentially causative role in cancer.
59. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 19:2000;1176-1179. A timely review proposing the analogy between acetylation and phosphorylation as ubiquitous methods of controlling cellular events. In rivalling kinases and phosphatases in this regard, HATs and HDACs are poised to become the next important class of drug targets in cancer and other therapeutic areas.
60. Gayther S.A., Batley S.J., Linger L., Bannister A., Thorpe K., Suet-Feung C., Diago Y., Russell P., Wilson A., Sowter H.M., et al. Mutations truncating EP300 acetylase in human cancers. Nat Genet. 24:2000;300-303. Truncating mutations in the gene encoding the HAT p300 were detected in 6 out of 193 epithelial cancers (6%). Such evidence for genetic deregulation of HATs and HDACs contributes to their validation as potential drug targets.
61. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suziki T., Tsuruo T., Nakashini O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumour activity against human tumours. Proc Natl Acad Sci USA. 96:1999;4592-4597. Exemplifies the ability to design synthetic, small-molecule inhibitors of HDACs which have excellent pharmacokinetic properties and show good antitumour activity and therapeutic indices in cancer models.
62. Lau O.D., Kundu T.K., Soccio R.E., Ait-Si-Ali S., Khalil E.M., Vassilev A., Wolffe A.P., Moran E. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell. 5:2000;589-595. The feasibility of discovering selective HAT inhibitors is exemplified using peptide-acetyl coenzyme A conjugates.
63. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature. 403:2000;41-45. This review develops the concept - known as the histone code - that a range of covalent modifications on the tail domains of histone proteins act in a sequential and combinatorial manner to regulate chromatin structure and gene transcription, thereby controlling cell fate.
64. II250, is shown to ubiquitinate histone H1 in a way that is essential for orderly gene expression in Drosophila.
65. Mizzen C.A., Allis D. New insights into an old modification. Science. 289:2000;2290-2291. A commentary on the paper by Pharm and Sauer [64•], setting it in the context of the histone code.
66. Kim M.S., Kwon H.J., Lee Y.M., Baek J.H., Jang J.E., Lee S.W., Moon E.J., Kim H.S., Lee S.K., Chung H.Y., et al. Histone deacetylases induce angiogenesis by negative regulation of tumour suppressor genes. Nat Med. 7:2001;437-443. This paper reports that HDACs are induced by tumour hypoxia, leading to downregulation of the tumour supressor genes p53 and VHL. An HDAC inhibitor upregulated these genes and downregulated hypoxia-inducible factor 1α (HIF-1α) and VEGF, resulting in inhibition of angiogenesis. The results indicate that HDAC inhibitors may be anti-angiogenic as well as antiproliferative.
67. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257. An up-to-date commentary on angiogenesis and its therapeutic implications.
68. White L.K., Wright W.E., Shay J.W. Telomerase inhibitors. Trends Biotechnol. 19:2001;114-120. A timely review of telomerase as a drug target and of progress with the discovery of telomerase inhibitors.
69. Read M., Harrison R.J., Romagnoli B., Tanious F.A., Gowan S.H., Reszka A.P., Wilson W.D., Kelland L.R., Neidle S. Structure-based design of selective and potent G-quadruplex-mediated telomerase inhibitors. Proc Natl Acad Sci USA. 98:2001;4844-4849. An example of the discovery of telomerase inhibitors, in this case acting via G-quadruplex binding.
70. Constantini P., Jacotot E., Decaudin D., Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst. 92:2000;1042-1053. A review of potential cancer drug targets in apoptotic signalling, with emphasis on mitochondrial involvement.
71. Horrobin D.F. Innovation in the pharmaceutical industry. J R Soc Med. 93:2000;3412-3415. A strong critique of the ability of genomics and other new technologies to deliver innovative drugs.
72. Brown P: Has R&D failed the pharmaceutical industry? Scrip Magazine 1994, July/August:3-4.
73. Gelmon K.A., Eisenhauer E.A., Harris A.L., Ratain M.J., Workman P. Anticancer agents targeting signalling molecules and cancer cell environment: challenges for drug development. J Natl Cancer Inst. 19:1999;1281-1287. A commentary on current issues in cancer drug development, focusing on clinical trials of novel cytostatic agents.
74. Torrance C.J., Jackson P.E., Montgomery E., Kinzler K.W., Vogelstein B., Wissner A., Nunes M., Frost P., Discafan C. Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 9:2000;1024-1028. Demonstration of the value of combining an EGF receptor kinase inhibitor with a cyclooxygenase-2 (COX2) inhibitor in the chemoprevention of colorectal cancer.